ALX Oncology (ALXO) Q4 2025 earnings summary

Executive summary

• Advanced clinical development of evorpacept and ALX2004, with both programs achieving significant milestones and positioned for pivotal studies by end of next year.

• Evorpacept demonstrated strong efficacy and tolerability in HER2-positive gastric and breast cancer, especially in CD47-high subgroups, and in indolent lymphoma.

• ALX2004 advanced through dose escalation with promising safety and preclinical efficacy data in EGFR-expressing solid tumors.

• Biomarker strategy for evorpacept validated, showing CD47 overexpression predicts response in both gastric and breast cancer trials.

• Closed a $150 million equity financing in February 2026, extending cash runway through the first half of 2028.

Financial highlights

• Ended Q4 2025 with $48.3 million in cash and investments before equity financing; post-financing, cash and investments totaled ~$188.7 million.

• Net proceeds from February 2026 equity offering were $140.4 million.

• GAAP net loss for Q4 2025 was $22.8 million ($0.42 per share), down from $29.2 million ($0.55 per share) in Q4 2024.

• Full-year 2025 GAAP net loss was $101.7 million ($1.90 per share), improved from $134.9 million ($2.58 per share) in 2024.

• R&D and G&A expenses decreased significantly year-over-year, contributing to a narrower net loss.

Outlook and guidance

• Sufficient cash to fund operations through the first half of 2028.

• Key milestones: Evorpacept biomarker analysis at ESMO Breast Cancer (May 2026), ALX2004 safety data (2H 2026), and ASPEN-09-Breast top-line data (mid-2027).

• Ongoing enrollment in multiple trials, focusing on HER2+ breast cancer and EGFR-expressing tumors.